Abstracts tagged "autoimmune diseases"

Abstract Number: 103 • 2019 ACR/ARP Annual Meeting
Serine Arginine-rich Splicing Factor 1 (SRSF1) Is Indispensable for Homeostasis and Function of Regulatory T Cells
Takayuki Katsuyama¹ and Vaishali R. Moulton ¹, ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Regulatory T cells (Tregs) are pivotal in enforcing immune tolerance to prevent and protect from autoimmunity. Defects in Tregs lead to unchecked immune cell…
Abstract Number: 1644 • 2019 ACR/ARP Annual Meeting
Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial
Masataka Kuwana¹, Kristin Highland ², Martina Gahlemann ³, Christopher Denton ⁴, Aryeh Fischer ⁵, Maureen Mayes ⁶, Virginia Steen ⁷, Dinesh Khanna ⁸, Yannick Allanore ⁹, Mannaig Girard ¹⁰, Margarida Alves ¹¹, Susanne Stowasser ¹¹ and Oliver Distler ¹², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁵University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Georgetown University, Washington, D.C., USA, Georgetown, ⁸Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ¹⁰Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹¹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Patients with diffuse cutaneous systemic sclerosis (dcSSc) are at greater risk of developing interstitial lung disease (ILD) than patients with limited cutaneous systemic sclerosis…
Abstract Number: 104 • 2019 ACR/ARP Annual Meeting
Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders
Santosh Vishwakarma¹, Gurulingappa Hallur ¹, Himanshu Agrawal ¹, Sharad Singh ¹, Annasaheb Kalange ¹, Seema Chikkur Gangadhar ¹, Shuvranshu PraharaJ ¹, Nafees Ahmad Quresh ¹, Srikanth Kanagal Gopinath ¹, Krishnakumar V ¹, Sameer Mahmood ¹, Rudresh G ¹, Mohd Zainuddin ¹, Rajendra Kristam ¹, Ishtiyaque Ahmad ¹, Ramachandraiah Gosu ¹, Purra Buchi Reddy ¹, N V S K Rao ¹, Saloni Mehra ², Jeyaraj D A ¹, Takeshi Yura ¹, Saravanakumar dhakshinamoorthy ¹, Sriram Rajagopal ¹, Dhanalakshmi Sivanandhan ³ and Sridharan Rajagopal ³, ¹Jubilant Biosys, Bangalore, India, ²Jubilant Chemsys, Noida, India, ³Jubilant Therapeutics, Bangalore, India
Background/Purpose: Citrullination of proteins is catalyzed by a family of enzymes called the peptidylarginine deiminases (PADs). While the citrullinated proteins may have physiological roles in differentiation,…
Abstract Number: 1650 • 2019 ACR/ARP Annual Meeting
Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)
Joerg Henes¹, Maria Carolina Oliveira ², Myriam Labopin ³, Manuela Badoglio ⁴, Hans Ulrich Scherer ⁵, Nicoletta Del Papa ⁶, Thomas Daikeler ⁷, Marc Schmalzing ⁸, Roland Schroers ⁹, Thierry Martin ¹⁰, Grégory Pugnet ¹¹, Belinda Simoes ¹², David Michonneau ¹³, Erik Marijt ¹⁴, Bruno Lioure ¹⁵, Jacques Olivier Bay ¹⁶, John Snowden ¹⁷, Montserrat Rovira ¹⁸, Anne Huynh ¹⁹, Francesco Onida ²⁰, Lothar Kanz ¹, Zora Marjanovic ²¹ and Dominique Farge ²², ¹University Hospital Tuebingen, Department of Internal Medicine II (Oncology, Haematology, Immunology and Rheumatology), Tuebingen, Germany, ²Ribeirão Preto Medical School, University of São Paulo, Sao Paulo, Brazil, ³EBMT Paris Study Office, Saint Antoine Hospital, Université Pierre et Marie Curie, Paris, France, ⁴EBMT Paris Study Office, Hôpital St Antoine, Paris, France, ⁵Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁶Scleroderma Clinic, Osp. G. Pini, Department of Rheumatology, Milan, Italy, ⁷University and University Hospital of Basel, Department of Rheumatology, Basel, Switzerland, ⁸Universitätsklinikum Würzburg, Department of Rheumatology/ Clinical Immunology, Wuerzburg, Germany, ⁹University Hospital of Bochum, Med. Klinik, Bochum, Germany, ¹⁰Hôpitaux Universitaires de Strasbourg Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares Est-Sud-Ouest (RESO), Strasbourg, France, ¹¹CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, ¹²Ribeirão Preto Medical School, University of São Paulo, Division of Hematology, Sao Paulo, Brazil, ¹³Hôpital Saint Louis & Université Paris 7, Denis Diderot, Department of Hematology, Paris, France, ¹⁴Leiden University Medical Center, Department of Hematology, Leiden, Netherlands, ¹⁵Strasbourg University Hospital, Department of Hematology, Strasbourg, France, ¹⁶CHU de Clermont Ferrand, Department of Hematology, Clermont Ferrand, France, ¹⁷Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, ¹⁸Hospital Clínic of Barcelona, Department of Haematology, Barcelona, Spain, ¹⁹UCT Oncopole, Department of Haematology, Toulouse, France, ²⁰Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, ²¹Saint Antoine Hospital, Department of Haematology, Paris, France, ²²Hôpital Saint-Louis, AP-HP Assistance Publique des Hôpitaux de Paris, Centre de Référence des Maladies Auto-Immunes Systémiques Rares d’Ile-de-France, Filière ‘FAI2R’, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), Université de Paris, EA 3518, Paris, France; Department of Medicine, McGill University, Montreal, QC, Canada, Paris, France
Background/Purpose: TThree randomized controlled trials in systemic sclerosis (SSc) demonstrated that autologous hematopoietic stem cell transplantation (aHSCT) is superior to standard cyclophosphamide therapy. This EBMT…
Abstract Number: 120 • 2019 ACR/ARP Annual Meeting
Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease
Geoffrey Gillard¹, Jennifer Proctor ¹, Melissa Brooks ¹, Tahirih Lamothe ¹, Sharon Hyzy ¹, Sean McDonough ¹, Rahul Palchaudhuri ², Anjali Bhat ¹, Ganapathy Sarma ¹, Prashant Bhattarai ¹, Pranoti Sawant ¹, Brad Pearse ¹, Charlotte McDonagh ¹, Anthony Boitano ¹ and Michael Cooke ¹, ¹Magenta Therapeutics, Cambridge, MA, ²Magenta Therapeutics, Cambridge
Background/Purpose: Autologous hematopoietic stem cell transplant (autoHSCT) is a highly effective treatment in selected patients with autoimmune diseases. AutoHSCT can induce long-term remission (up to…
Abstract Number: 1807 • 2019 ACR/ARP Annual Meeting
Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease
George J. Kahaly ¹, Saba Sile ², Elizabeth H.Z. Thompson ², Thomas Vescio ³, Renee Perdok ³, Jeffrey W. Sherman³, Terry J. Smith ⁴ and Raymond S. Douglas ⁵, ¹Johannes Gutenberg University Medical Center, Mainz, Germany, ²Horizon Therapeutics plc, Brisbane, CA, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴University of Michigan Kellogg Eye Center, Ann Arbor, MI, ⁵Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Thyroid eye disease (TED) is a debilitating autoimmune disorder characterized by inflammation and exophthalmia along with significantly altered appearance and vision changes. TED is…
Abstract Number: 253 • 2019 ACR/ARP Annual Meeting
A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease
Maria Lopez-Olivo¹, Noha Abdel-Wahab ¹ and Maria E. Suárez-Almazor ², ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) are increasingly used in the treatment of cancer. To date, no clinical trials exist evaluating the use of ICI in…
Abstract Number: 1833 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial
Kristin Highland¹, Oliver Distler ², Masataka Kuwana ³, Yannick Allanore ⁴, Shervin Assassi ⁵, Arata Azuma ⁶, Arnaud Bourdin ⁷, Christopher Denton ⁸, Jörg Distler ⁹, Anna Maria Hoffmann-Vold ¹⁰, Dinesh Khanna ¹¹, Maureen Mayes ⁵, Ganesh Raghu ¹², Madelon Vonk ¹³, Martina Gahlemann ¹⁴, Mannaig Girard ¹⁵, Susanne Stowasser ¹⁶, Donald Zoz ¹⁷, Aryeh Fischer ¹⁸ and Toby Maher ¹⁹, ¹Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ⁴Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁶Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ⁷PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214 and Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, Montpellier, France, Montpellier, ⁸University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ¹⁰Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²University of Washington, Seattle, USA, Seattle, ¹³Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ¹⁴Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹⁵Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ¹⁸University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ¹⁹National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the annual rate of decline in forced vital capacity…
Abstract Number: 374 • 2019 ACR/ARP Annual Meeting
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Eric Matteson¹, Clive Kelly ², Jörg Distler ³, Anna Maria Hoffmann-Vold ⁴, James Seibold ⁵, Shikha Mittoo ⁶, Oliver Distler ⁷, Rainer-Georg Goeldner ⁸, Rozsa Schlenker-Herceg ⁹, Susanne Stowasser ¹⁰, Manuel Quaresma ¹⁰ and Kevin Flaherty ¹¹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle, United Kingdom, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁵Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, ⁶University Health Network, Toronto, Ontario, Canada, Toronto, Canada, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Some patients with autoimmune disease develop progressive fibrosing interstitial lung disease (ILD) characterized by increasing fibrosis on HRCT, decline in lung function, worsening symptoms…
Abstract Number: 2033 • 2019 ACR/ARP Annual Meeting
IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells
Angie Hammond¹, Sean Parghi ¹, Nathan Wright ¹, Ethan Grant ¹, James Taylor ¹ and Matthew Warr ¹, ¹Gilead Sciences, Inc., Foster City, CA
Background/Purpose: A hallmark of lupus is the presence of antinuclear autoantibodies, including those against RNA-protein complexes and double-stranded DNA (dsDNA).1,2 FcγR-mediated internalization of these nucleic…
Abstract Number: 843 • 2018 ACR/ARHP Annual Meeting
Localization of the Voltage-Gated Sodium Channel 1.7 in Peripheral Monocytes Contributes to Activation of BAFF Signaling in Monocytes of Patients with Primary Sjögren’s Syndrome
Keiko Yoshimoto, Yumi Ikeda, Katsuya Suzuki and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: In our previous study, we have reported that IL-6 production was robustly increased in BAFF-stimulated peripheral monocytes of patients with primary Sjögren’s syndrome (pSS)…
Abstract Number: 1182 • 2018 ACR/ARHP Annual Meeting
The Disproportionate High Risk of Re-Fracture after Osteoporotic Treatment in Patients with Autoimmune Diseases
Wen-Nan Huang¹, Yi-Ming Chen¹, Wei-Ting Hung², Yu-Wan Liao³ and Yi-Hsing Chen¹, ¹Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ³Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Patients with autoimmune diseases are associated with an increased risk of osteoporotic fracture. Anti-osteoporotic treatment could diminish re-fracture rates in post-menopause women. However, treatment…
Abstract Number: 1584 • 2018 ACR/ARHP Annual Meeting
Evaluation of the Performance of the 2016 American College of Rheumatology-European League Against Rheumatism (Acr-Eular) Classification Criteria for Primary Sjogren`S Syndrome in Different Centers of Argentina
Hugo Najera¹, Marta Mamani², Anastasia Secco¹, Fernando Melo³, Cristian Troitiño⁴, Felix Romanini Sr.², Emmanuel Guerra², Antonio Catalan Pellet⁵, Silvia Beatriz Papasidero⁶, Rodrigo Aguila Maldonado⁷, Mercedes Garcia⁷, Mariano Rivero⁸, Juan Carlos Barreira⁹, ivan remolina¹⁰, A. perdomo¹¹, quevedo mayorga¹⁰, M.J. santacruz¹² and j demarchi¹⁰, ¹Rheumatology Section, Hospital Bernardino Rivadavia, CABA, Argentina, ²Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ³Rheumatology Department, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁴Reumatologia, Hospital Bernardino Rivadavia, CAPITAL FEDERAL, Argentina, ⁵Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁶Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, Buenos Aires, Argentina, ⁷Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ⁸Rheumatology, Consultorios Externos Vacarezza,Alberdi,Pcia Buenos Aires, Pcia Buenos Aires, Argentina, ⁹Rheumatology Unit, Hospital Británico, Buenos Aires, Buenos Aires, Argentina, ¹⁰hospital britanico, Buenos Aires, Argentina, ¹¹hospital nuestra señora de la merced, alberti, Argentina, ¹²hospital tornu, Buenos Aires, Argentina
Background/Purpose: Primary Sjögren`s Syndrome (pSS) is a multisystemic, autoimmunity disease, characterized mainly by the hypofunction of the salivary and lacrimal glands, however the clinical spectrum…
Abstract Number: 1771 • 2018 ACR/ARHP Annual Meeting
Long-Term Survival of Renal Transplantation in Rapidly Progressive Glomerulonephritis (RPGN). Study of 43 Cases from a Single Center
Belén Atienza-Mateo¹, Lara Sánchez-Bilbao¹, José Luis Martín-Varillas¹, Marina de Cos-Gómez², Íñigo González-Mazón¹, Diana Prieto Peña³, Monica Calderón Goercke³, Emilio Rodrigo Calabia², Juan Carlos Ruiz San Millán², Miguel Angel González-Gay¹ and Ricardo Blanco⁴, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Nephrology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
Background/Purpose: Rapidly Progressive Glomerulonephritis (RPGN) is characterized histology by presence of crescents and clinically by rapid and severe decline in kidney function. Thus, it may…
Abstract Number: 1915 • 2018 ACR/ARHP Annual Meeting
Big Data Analysis of Autoimmune Diseases Induced By Cancer Immunotherapies: Identifying Pharmacological Patterns of Organ-Specific Involvement
Soledad Retamozo^1,2,3, Alejandra Flores-Chavez^4,5,6, Belchin Kostov⁷, Antoni Sisó-Almirall⁸, Marta Pérez-de-Lis⁹, Roberto Pérez-Alvarez¹⁰, Pilar Brito-Zerón^11,12, Munther A Khamashta¹³ and Manuel Ramos-Casals¹⁴, ¹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ⁵Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁶Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ⁷ABS Les Corts, CAPSE, Research Group in Primary Care, IDIBAPS, ABS Les Corts, CAPSE, Barcelona, Spain, ⁸Primary Care Research Group, IDIBAPS, Centre d’Assistència Primària ABS Les Corts, GESCLINIC, Barcelona, Barcelona, Spain, ⁹Department of Anesthesia, Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain, ¹⁰Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Vigo, Spain, ¹¹Autoimmune Diseases Unit, Department of Internal Medicine, Hospital CIMA-Sanitas, Barcelona, Barcelona, Spain, ¹²Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Barcelona, Spain, ¹³Lupus Research Unit, The Rayne Institute, Lupus Research Unit, The Rayne Institute, Kings' College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ¹⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona., Barcelona, Spain
Background/Purpose: The scenario of biological-triggered autoimmune diseases has dramatically changed in recent years due to the increasing use of biologics in patients with solid cancers. Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].